Irbesartan v placebo for progression to nephropathy in type 2 diabetes, hypertension, and persistent microalbuminuria at 2 years‡
| Irbesartan dose | Irbesartan | Placebo | Adjusted hazard ratio (95% CI) | NNT (CI) |
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; NNT and its CI calculated by using hazard ratios provided in the article; hazard ratios adjusted for baseline microalbuminuria and blood pressure during the study. | ||||
| 150 mg/day | 9.7% | 14.9% | 0.56 (0.31 to 0.99) | 16 (10 to 728) |
| 300 mg/day | 5.2% | 14.9% | 0.32 (0.15 to 0.65) | 11 (8 to 21) |